BACKGROUND: We sought to evaluate and describe our centre's experience with the Amplatzer vascular plug (AVP) for the occlusion of common and internal iliac arteries (CIA; IIA) during endovascular aortic aneurysm repair (EVAR). METHODS: We performed a retrospective analysis of 20 consecutive patients between October 2006 and December 2007, who underwent occlusion of the CIA or IIA before or during EVAR to prevent endoleak. RESULTS: Among these 20 patients, 21 occlusion procedures occurred and 20 were successful. In the only unsuccessful case, the patient had EVAR, but occlusion with an AVP was not possible because of severe narrowing at the origin of the vessel. Of the successfully treated patients, 2 presented with ruptured aneurysms, whereas the others had elective procedures. Eleven patients received aortouni-iliac grafts and femoral-femoral bypass, and 9 patients received a bifurcated stent graft. In 5 patients, the AVP occlusion and EVAR procedures were staged; in these cases occlusion occurred first, followed by EVAR on average 29 (standard deviation [SD] 23) days later. We deployed 7 AVPs in the CIA, whereas 13 were deployed in the IIA. The average diameter of the vessels occluded was 10 (SD 1) mm and the average size of the device used was 13 (SD 1) mm, representing a device diameter 28% (SD 2%) greater than the vessel diameter. We used a single device in 18 patients, whereas 2 devices were deployed in the same artery in 2 patients. Four patients underwent concomitant coil embolization. On follow-up computed tomography (CT) scans, all occlusion procedures were clinically successful. At the 14-month (SD 1 mo) follow-up, 4 patients had a small type-II endoleak unrelated to the occlusion procedure and 1 had a type-I endoleak that required graft limb extension. Four patients had buttock claudication but none had changes in sexual function, ischemic complications or device dislodgement on CT scans. CONCLUSION: The AVP is a safe and effective method to occlude the CIA and IIA in patients undergoing EVAR.
BACKGROUND: We sought to evaluate and describe our centre's experience with the Amplatzer vascular plug (AVP) for the occlusion of common and internal iliac arteries (CIA; IIA) during endovascular aortic aneurysm repair (EVAR). METHODS: We performed a retrospective analysis of 20 consecutive patients between October 2006 and December 2007, who underwent occlusion of the CIA or IIA before or during EVAR to prevent endoleak. RESULTS: Among these 20 patients, 21 occlusion procedures occurred and 20 were successful. In the only unsuccessful case, the patient had EVAR, but occlusion with an AVP was not possible because of severe narrowing at the origin of the vessel. Of the successfully treated patients, 2 presented with ruptured aneurysms, whereas the others had elective procedures. Eleven patients received aortouni-iliac grafts and femoral-femoral bypass, and 9 patients received a bifurcated stent graft. In 5 patients, the AVP occlusion and EVAR procedures were staged; in these cases occlusion occurred first, followed by EVAR on average 29 (standard deviation [SD] 23) days later. We deployed 7 AVPs in the CIA, whereas 13 were deployed in the IIA. The average diameter of the vessels occluded was 10 (SD 1) mm and the average size of the device used was 13 (SD 1) mm, representing a device diameter 28% (SD 2%) greater than the vessel diameter. We used a single device in 18 patients, whereas 2 devices were deployed in the same artery in 2 patients. Four patients underwent concomitant coil embolization. On follow-up computed tomography (CT) scans, all occlusion procedures were clinically successful. At the 14-month (SD 1 mo) follow-up, 4 patients had a small type-II endoleak unrelated to the occlusion procedure and 1 had a type-I endoleak that required graft limb extension. Four patients had buttock claudication but none had changes in sexual function, ischemic complications or device dislodgement on CT scans. CONCLUSION: The AVP is a safe and effective method to occlude the CIA and IIA in patients undergoing EVAR.
Authors: J Cynamon; D Lerer; F J Veith; B H Taragin; S I Wahl; J L Lautin; T Ohki; S Sprayregen Journal: J Vasc Interv Radiol Date: 2000-05 Impact factor: 3.464
Authors: C W Lee; J A Kaufman; C M Fan; S C Geller; D C Brewster; R P Cambria; G M Lamuraglia; J P Gertler; W M Abbott; A C Waltman Journal: J Vasc Interv Radiol Date: 2000-05 Impact factor: 3.464
Authors: Kristina I Ringe; Jürgen Weidemann; Herbert Rosenthal; Marc Keberle; Ajay Chavan; Stefan Baus; Michael Galanski Journal: Cardiovasc Intervent Radiol Date: 2007-09-01 Impact factor: 2.740
Authors: L M Wolpert; K P Dittrich; M J Hallisey; P P Allmendinger; J J Gallagher; K Heydt; R Lowe; M Windels; A D Drezner Journal: J Vasc Surg Date: 2001-06 Impact factor: 4.268
Authors: M Mehta; F J Veith; T Ohki; J Cynamon; K Goldstein; W D Suggs; R A Wain; D W Chang; S G Friedman; L A Scher; E C Lipsitz Journal: J Vasc Surg Date: 2001-02 Impact factor: 4.268
Authors: R K Greenberg; M Lawrence-Brown; G Bhandari; D Hartley; W Stelter; T Umscheid; T Chuter; K Ivancev; R Green; B Hopkinson; J Semmens; K Ouriel Journal: J Vasc Surg Date: 2001-02 Impact factor: 4.268
Authors: Frank R Arko; Bradley B Hill; Cornelius Olcott; E John Harris; Thomas J Fogarty; Christopher K Zarins Journal: J Endovasc Ther Date: 2002-12 Impact factor: 3.487
Authors: Peter M T Pattynama; Alexandra Wils; Edwin van der Linden; Lukas C van Dijk Journal: Cardiovasc Intervent Radiol Date: 2007-06-02 Impact factor: 2.740